Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Dec 07, 2022	USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis SOLANA BEACH, Calif. , Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that the United States Patent	View HTML PDF Version
Toggle Summary Apr 20, 2023	United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI The Company Will Submit for FDA Orange-Book Listing in the Near Term SOLANA BEACH, Calif. , April 20, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI®	View HTML PDF Version
Toggle Summary Nov 14, 2023	United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI The Company Will Submit for FDA Orange-Book Listing in the Near Term SOLANA BEACH, Calif. , Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®	View HTML PDF Version
Toggle Summary Sep 15, 2015	U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001 States Patients With Diabetic Gastroparesis May Have Unpredictable Gastric Emptying and Altered Absorption of Orally-Administered Hypoglycemic Drugs	View HTML U.S. Food and Drug Administration's (FDA) Draft Guidance is Consistent With Evoke's Current Phase 3 Study Design and Endpoint for EVK-001 18.7 KB
Toggle Summary May 09, 2023	Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources Patients treated with Gimoti® (metoclopramide) nasal spray showed statistically significant fewer emergency department visits, inpatient hospitalizations, and physician office visits than patients who were treated with oral metoclopramide SOLANA BEACH, Calif.	View HTML PDF Version
Toggle Summary May 23, 2022	Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide Supports Safety Profile of Only Approved Molecule in US to Treat Symptoms of Acute and Recurrent Diabetic	View HTML PDF Version
Toggle Summary Apr 04, 2017	Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA SOLANA BEACH, Calif., April 04, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company recently completed a positive Type A meeting with the U.S.	View HTML Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA 14.9 KB
Toggle Summary May 18, 2022	Patient Experience Survey Reported Positive Findings for GIMOTI® Research Study Among Patients Demonstrated Favorable Acceptance and Utilization of GIMOTI SOLANA BEACH, Calif. and CHICAGO , May 18, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and	View HTML PDF Version
Toggle Summary May 01, 2023	New GIMOTI Patent Listed in FDA Orange Book Broad Formulation Patent Expands Protection for Gimoti SOLANA BEACH, Calif. , May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide)	View HTML PDF Version
Toggle Summary Feb 17, 2022	GIMOTI® Commercialization Update New Research Study Demonstrates Increased Acceptance Among Healthcare Providers Patient Testimonial Videos Detail Benefits Included and Available on GimotiRx.com Expanded Coverage with recent New York Medicaid Approval SOLANA BEACH, Calif. , Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma ,	View HTML PDF Version